Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver D Howes

Showing results (271-280 of 329) with videos related to

Pageof 33
Sort By:
Journal of Psychopharmacology (Oxford, England)|December 15, 2017
Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for PsychopharmacologyOliver D Howes, Maria Rogdaki, James L Findon, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 12, 2014
Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosisAlice Egerton, James M Stone, Christopher A Chaddock, et al.
Frontiers in Neurology|November 12, 2020
Patterns of Mitochondrial TSPO Binding in Cerebral Small Vessel Disease: An <i>in vivo</i> PET Study With Neuropathological ComparisonPaul Wright, Mattia Veronese, Ndabezinhle Mazibuko, et al.
Schizophrenia Bulletin|January 5, 2021
Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant SchizophreniaGrant McQueen, Kyra-Verena Sendt, Amy Gillespie, et al.
Molecular Psychiatry|June 23, 2021
Correction: Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET studyMaria Rogdaki, Céline Devroye, Mariasole Ciampoli, et al.
JAMA Psychiatry|December 10, 2025
Role of Serotonin in the Neurobiology of Schizophrenia and Association With Negative SymptomsMartin Osugo, Thomas Whitehurst, David Erritzoe, et al.
Schizophrenia (Heidelberg, Germany)|March 3, 2022
Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophreniaFanni Krajner, Laila Hadaya, Grant McQueen, et al.
Psychopharmacology|April 21, 2022
The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging studyMichael A P Bloomfield, Yumeya Yamamori, Chandni Hindocha, et al.
Molecular Psychiatry|May 13, 2021
Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET studyMaria Rogdaki, Céline Devroye, Mariasole Ciampoli, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 24, 2021
The impact of the prolonged COVID-19 pandemic on stress resilience and mental health: A critical review across wavesMirko Manchia, Anouk W Gathier, Hale Yapici-Eser, et al.
Pageof 33

Showing results (271-280 of 329) with videos related to

Sort By:
Pageof 33
Journal of Psychopharmacology (Oxford, England)|December 15, 2017
Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for PsychopharmacologyOliver D Howes, Maria Rogdaki, James L Findon, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 12, 2014
Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosisAlice Egerton, James M Stone, Christopher A Chaddock, et al.
Frontiers in Neurology|November 12, 2020
Patterns of Mitochondrial TSPO Binding in Cerebral Small Vessel Disease: An <i>in vivo</i> PET Study With Neuropathological ComparisonPaul Wright, Mattia Veronese, Ndabezinhle Mazibuko, et al.
Schizophrenia Bulletin|January 5, 2021
Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant SchizophreniaGrant McQueen, Kyra-Verena Sendt, Amy Gillespie, et al.
Molecular Psychiatry|June 23, 2021
Correction: Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET studyMaria Rogdaki, Céline Devroye, Mariasole Ciampoli, et al.
JAMA Psychiatry|December 10, 2025
Role of Serotonin in the Neurobiology of Schizophrenia and Association With Negative SymptomsMartin Osugo, Thomas Whitehurst, David Erritzoe, et al.
Schizophrenia (Heidelberg, Germany)|March 3, 2022
Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophreniaFanni Krajner, Laila Hadaya, Grant McQueen, et al.
Psychopharmacology|April 21, 2022
The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging studyMichael A P Bloomfield, Yumeya Yamamori, Chandni Hindocha, et al.
Molecular Psychiatry|May 13, 2021
Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET studyMaria Rogdaki, Céline Devroye, Mariasole Ciampoli, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 24, 2021
The impact of the prolonged COVID-19 pandemic on stress resilience and mental health: A critical review across wavesMirko Manchia, Anouk W Gathier, Hale Yapici-Eser, et al.
Pageof 33